Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer

作者全名："Yin, Shuping; Cui, Han; Qin, Shuang; Yu, Shengnan"

作者地址："[Yin, Shuping; Cui, Han] Changxing Peoples Hosp Zhejiang Huzhou, Dept Obstet & Gynecol, Changxing 313100, Peoples R China; [Qin, Shuang] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Radiat Oncol, Wuhan 430030, Peoples R China; [Yu, Shengnan] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing 400042, Peoples R China"

通信作者："Qin, S (通讯作者)，Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Radiat Oncol, Wuhan 430030, Peoples R China.; Yu, SN (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing 400042, Peoples R China."

来源：BIOMEDICINE & PHARMACOTHERAPY

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:001068838000001

JCR分区：Q1

影响因子：7.5

年份：2023

卷号：166

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：TGF-beta; Cervical cancer; Immunotherapy; Bispecific antibody; PD-L1

摘要："Cervical cancer is a serious threat to women's health globally. Therefore, identifying key molecules associated with cervical cancer progression is essential for drug development, disease monitoring, and precision therapy. Recently, TGF-beta (transforming growth factor-beta) has been identified as a promising target for cervical cancer treatment. For advanced cervical cancer, TGF-beta participates in tumor development by improving metastasis, stemness, drug resistance, and immune evasion. Accumulating evidence demonstrates that TGF-beta blockade effectively improves the therapeutic effects, especially immunotherapy. Currently, agents targeting TGF-beta and immune checkpoints such as PD-L1 have been developed and tested in clinical studies. These bispecific antibodies might have the potential as therapeutic agents for cervical cancer treatment in the future."

基金机构：National Natural Science Foundation of China [82203007]

基金资助正文：<B>Funding</B> This work was supported by the National Natural Science Foundation of China (Nos. 82203007) .